National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Doravirine (Pifeltro®) is indicated in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.


NCPE Assessment Process Complete
Rapid review commissioned 06/12/2018
Rapid review completed 16/01/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that doravirine (Pifeltro®) not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.